9 oct 2018
CPhI Worldwide 2018
Global Napi Pharmaceuticals

Global Napi Pharmaceuticals

Exhibitor at CPhI Worldwide 2018 stand 14.1F10

About us

  Global Pharmaceutical Group   GLOBAL NAPI PHARMACEUTICALS (GNP) is a local investment project established in 1994 dealing with pharmaceutical formulations production in Egypt. In addition to production of GNP products, license agreements were established with multinational pharmaceutical companies, of them, MSD, Sanofi, Novartis, Stada, Elerte, SUN and others. GNP products are covering a wide range of therapeutic areas, with 130 local brands in tablets, capsules, solutions, syrups, ointments, creams, gels, and suppositories.   GNP products are produced with the GMP standards. GNP is awarded ISO 9001 for quality, SO 14001 for environment and ISO 17025 for quality lab accreditation certificates. GNP was inspected, registered and the products were marketed in Yemen, Sudan, Tanzania, Uganda, Kenya and Eastern Europe (CIS). The company was also inspected and accepted by Romanian Health authorities for European GMP (PIC/s).   Global Pharmaceutical Industries (GPI) is established, designated for sterile injectable products; in the form of vials and ampoule in solution and lyophilized products. The products were in the market since November 2011. Also Pfizer, Amoun, SUN, IDI, EVA pharm and others are in contract manufacturing agreements with GPI for production of their injectable products. Around 30 brands are now in the market. GPI was inspected and approved by Romanian Health Authorities for European GMP (PIC/s), as well as Sudan and Yemen Health Authorities.   Global Advanced Pharmaceuticals (GAP) is a mega project in Egypt, composed of 6 modules of production for different pharmaceutical forms, Solid Dosage forms, Liquids, Ophthalmic Preparations, Large Volume Intravenous Fluids, Cephalosporin and Oncology products. The first phase of production, the Solid Dosage forms (Capsules and Tablets) and Blow-Fill-Seal (BFS) line, mainly for ophthalmic preparations, started production in the third quarter 2018. The capacity of the Solid Dosage form exceeds 100 Million blisters per year.  The BFS line is designed for production of multiple and unit-dose forms. Partners are invited to join GAP project in any form of business style.   Three sister companies, the scientific offices MMP and 3MP (for sales and marketing), Ramco (for import and export) and RamcoPharm (for local distribution of pharmaceutical products), are working in an integrated network with Global Pharma Group.   For more details, visit our website: www.globalnapi.com       

Specs about this supplier

Sales markets
Sales markets: Western Europe | Eastern Europe | Middle East | Asia | Australia | North America | Africa | Central/South America
Affiliated categories:

Products featured at CPhI Worldwide 2018

View all our products (107)
Global Napi Pharmaceuticals

Event information

CPhI Worldwide 2018

9 - 11 October 2018 Madrid, Spain Visit us at stand 14.1F10